M. Dolled-Filhart

Oncology · 2004–2016

A researcher in the Science corpus: 4 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom M. Dolled-Filhart trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. R. Camp

Who trusts M. Dolled-Filhart overall

  1. Hideaki Mizuno

Papers from M. Dolled-Filhart's perspective

Ordered by how strongly the researchers M. Dolled-Filhart trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Validation of Tissue Microarray Technology in Breast Carcinoma (Laboratory Investigation)
  2. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. (American Journal of Pathology)
  3. Connections and Regulation of the Human Estrogen Receptor (Science)
  4. Automated subcellular localization and quantification of protein expression in tissue microarrays (Nature Medicine)
  5. Pembrolizumab versus Ipilimumab in Advanced Melanoma. (New England Journal of Medicine)
  6. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the… (Journal of Clinical Oncology)
  7. Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 (Journal of Immunology)
  8. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. (The Lancet Oncology)
  9. PD-1 blockade in tumors with mismatch repair deficiency. (Journal of Clinical Oncology)
  10. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma (Cancer Research)

Their papers